DK1896507T3 - Anti-CD71-monoklonale antistoffer og anvendelser deraf til behandling af maligne tumorceller - Google Patents

Anti-CD71-monoklonale antistoffer og anvendelser deraf til behandling af maligne tumorceller

Info

Publication number
DK1896507T3
DK1896507T3 DK06795343.0T DK06795343T DK1896507T3 DK 1896507 T3 DK1896507 T3 DK 1896507T3 DK 06795343 T DK06795343 T DK 06795343T DK 1896507 T3 DK1896507 T3 DK 1896507T3
Authority
DK
Denmark
Prior art keywords
monoclonal antibodies
applications
treatment
tumor cells
malignant tumor
Prior art date
Application number
DK06795343.0T
Other languages
English (en)
Inventor
Laurence Boumsell
Jean Kadouche
Armand Bensussan
Original Assignee
Inst Nat Sante Rech Med
Monoclonal Antibodies Therapeu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Monoclonal Antibodies Therapeu filed Critical Inst Nat Sante Rech Med
Application granted granted Critical
Publication of DK1896507T3 publication Critical patent/DK1896507T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK06795343.0T 2005-06-15 2006-06-14 Anti-CD71-monoklonale antistoffer og anvendelser deraf til behandling af maligne tumorceller DK1896507T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/154,262 US7736647B2 (en) 2005-06-15 2005-06-15 Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells
PCT/IB2006/002331 WO2007000671A2 (en) 2005-06-15 2006-06-14 Anti-cd71 monoclonal antibodies and uses thereof for treating malignant tumour cells

Publications (1)

Publication Number Publication Date
DK1896507T3 true DK1896507T3 (da) 2010-06-07

Family

ID=37573538

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06795343.0T DK1896507T3 (da) 2005-06-15 2006-06-14 Anti-CD71-monoklonale antistoffer og anvendelser deraf til behandling af maligne tumorceller

Country Status (10)

Country Link
US (2) US7736647B2 (da)
EP (1) EP1896507B1 (da)
JP (1) JP5185815B2 (da)
AT (1) ATE459653T1 (da)
CA (1) CA2612486A1 (da)
DE (1) DE602006012672D1 (da)
DK (1) DK1896507T3 (da)
ES (1) ES2341625T3 (da)
PL (1) PL1896507T3 (da)
WO (1) WO2007000671A2 (da)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110074879A (ko) * 2008-10-23 2011-07-04 에프. 호프만-라 로슈 아게 면역글로불린을 암호화하는 핵산의 측정 방법
RU2704802C2 (ru) * 2009-07-22 2019-10-31 Актиниум Фармасьютикалз Инк. Способы получения радиоиммуноконъюгатов
WO2011130164A2 (en) * 2010-04-13 2011-10-20 The Regents Of The University Of California Unconjugated anti-tfr antibodies and compositions thereof for the treatment of cancer
FR2959416B1 (fr) * 2010-05-03 2012-06-22 Monoclonal Antibodies Therapeutics Mat Biopharma Utilisation d'anticorps anti-cd71 pour la preparation d'un medicament
PT2646470T (pt) 2010-11-30 2017-05-03 Hoffmann La Roche Anticorpos anti-recetor da transferrina de baixa afinidade e a sua utilização na transferência de scfv terapêuticos através da barreira hematoencefálica
US9623117B2 (en) * 2011-04-04 2017-04-18 Wisconsin Alumni Research Foundation Method for selective targeting and entry of bacterial toxins to cells
JP2014518615A (ja) * 2011-04-22 2014-08-07 エマージェント プロダクト デベロップメント シアトル, エルエルシー 前立腺特異的膜抗原結合タンパク質および関連組成物ならびに方法
US9696312B2 (en) 2011-09-02 2017-07-04 The Trustees Of Columbia University In The City Of New York Diagnosis and treatment of cancer expressing ILT3 or ILT3 ligand
SG11201401518TA (en) 2011-10-28 2014-05-29 Teva Pharmaceuticals Australia Pty Ltd Polypeptide constructs and uses thereof
CN104662044B (zh) 2012-08-24 2018-10-30 加利福尼亚大学董事会 用于治疗ror1癌症并抑制转移的抗体和疫苗
AU2016258988A1 (en) 2015-05-04 2017-12-07 Cytomx Therapeutics, Inc Anti-ITGa3 antibodies, activatable anti-ITGa3 antibodies, and methods of use thereof
BR112017023862A2 (pt) 2015-05-04 2018-07-17 Cytomx Therapeutics Inc anticorpos anti-cd71, anticorpos anti-cd71 ativáveis, e métodos de uso destes
EP3325006A4 (en) 2015-07-17 2019-03-06 The Trustees of Columbia University in the City of New York METHOD FOR TREATING CD166-EXPRESSIVE CANCER
EP3352760A4 (en) 2015-09-21 2019-03-06 Aptevo Research and Development LLC CD3 BINDING POLYPEPTIDES
CA3014934A1 (en) 2016-03-04 2017-09-08 JN Biosciences, LLC Antibodies to tigit
MA45328A (fr) * 2016-04-01 2019-02-06 Avidity Biosciences Llc Compositions acide nucléique-polypeptide et utilisations de celles-ci
US20190240346A1 (en) 2016-06-20 2019-08-08 Genahead Bio, Inc. Antibody-drug conjugate
IL299099A (en) 2016-06-27 2023-02-01 Univ California Combinations of cancer treatments
US10597438B2 (en) 2016-12-14 2020-03-24 Janssen Biotech, Inc. PD-L1 binding fibronectin type III domains
WO2018111978A1 (en) 2016-12-14 2018-06-21 Janssen Biotech, Inc. Cd137 binding fibronectin type iii domains
CA3046963A1 (en) 2016-12-14 2018-06-21 Janssen Biotech, Inc. Cd8a-binding fibronectin type iii domains
SG11201906200WA (en) 2017-01-06 2019-08-27 Avidity Biosciences Llc Nucleic acid-polypeptide compositions and methods of inducing exon skipping
WO2018165619A1 (en) 2017-03-09 2018-09-13 Cytomx Therapeutics, Inc. Cd147 antibodies, activatable cd147 antibodies, and methods of making and use thereof
GB201711809D0 (en) 2017-07-21 2017-09-06 Governors Of The Univ Of Alberta Antisense oligonucleotide
EP3762420A1 (en) 2018-03-09 2021-01-13 CytomX Therapeutics, Inc. Activatable cd147 antibodies and methods of making and use thereof
KR102258015B1 (ko) * 2019-05-15 2021-05-27 강원대학교 산학협력단 암 줄기세포 세포막 단백질에 특이적인 항체 및 그 응용
KR102258014B1 (ko) * 2019-05-15 2021-05-27 강원대학교 산학협력단 암 줄기세포 세포막 단백질에 특이적인 항체 및 그 응용
KR20220041851A (ko) * 2019-07-19 2022-04-01 우시 바이올로직스 아일랜드 리미티드 접합을 위한 폴리펩티드 복합체 및 이의 용도
WO2021061867A1 (en) 2019-09-23 2021-04-01 Cytomx Therapeutics, Inc. Anti-cd47 antibodies, activatable anti-cd47 antibodies, and methods of use thereof
WO2021076546A1 (en) * 2019-10-14 2021-04-22 Aro Biotherapeutics Company Cd71 binding fibronectin type iii domains
US11781138B2 (en) 2019-10-14 2023-10-10 Aro Biotherapeutics Company FN3 domain-siRNA conjugates and uses thereof
US11820824B2 (en) 2020-06-02 2023-11-21 Arcus Biosciences, Inc. Antibodies to TIGIT
BR112023021325A2 (pt) 2021-04-14 2023-12-19 Aro Biotherapeutics Company Domínios de fibronectina tipo iii de ligação a cd71
MX2024002753A (es) 2021-09-01 2024-05-20 Biogen Ma Inc Anticuerpos anti receptor de transferrina y usos de los mismos.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5308626A (en) 1985-06-28 1994-05-03 Toni N. Mariani Lymphokine activated effector cells for antibody-dependent cellular cytotoxicity (ADCC) treatment of cancer and other diseases
CA2081368A1 (en) 1990-03-27 1991-09-28 Ian S. Trowbridge Method for inhibiting cell growth and compositions useful therefor
US5762932A (en) * 1990-04-26 1998-06-09 University Of Iowa Research Foundation Combined treatment of iron depletion and IgG antibody
US6107090A (en) * 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
CA2569692C (en) 2004-06-07 2015-07-21 Raven Biotechnologies, Inc. Transferrin receptor antibodies

Also Published As

Publication number Publication date
US8409573B2 (en) 2013-04-02
DE602006012672D1 (de) 2010-04-15
ES2341625T3 (es) 2010-06-23
EP1896507A2 (en) 2008-03-12
WO2007000671A2 (en) 2007-01-04
WO2007000671A3 (en) 2007-04-26
JP2009509497A (ja) 2009-03-12
ATE459653T1 (de) 2010-03-15
EP1896507B1 (en) 2010-03-03
US20110311544A1 (en) 2011-12-22
US7736647B2 (en) 2010-06-15
JP5185815B2 (ja) 2013-04-17
CA2612486A1 (en) 2007-01-04
PL1896507T3 (pl) 2010-08-31
US20060286030A1 (en) 2006-12-21

Similar Documents

Publication Publication Date Title
DK1896507T3 (da) Anti-CD71-monoklonale antistoffer og anvendelser deraf til behandling af maligne tumorceller
SG171690A1 (en) Treatment of protein degradation disorders
CR20200465A (es) Agentes anticuerpos anti-cd25
TW200738748A (en) Human monoclonal antibody human CD134 (OX40) and methods of making and using same
TW200740844A (en) Novel MAdCAM antibodies
RU2448096C3 (ru) Диарилгидантоины
EA200702053A1 (ru) Антитела против cd38 для лечения множественной миеломы
UA101478C2 (ru) Соединения, полезные как ингибиторы raf-киназы
UA113388C2 (xx) ЗАСТОСУВАННЯ АНТИТІЛА ПРОТИ с-МЕТ
DK1853602T3 (da) Kemiske forbindelser
MX2010005022A (es) Anticuerpos que unen celulas dendriticas y epiteliales 205 (dec-205) humanas.
NO20073788L (no) Kjemiske forbindelser
TW200716606A (en) Chemical compounds
UA92505C2 (ru) Композиции на основе антитела против cd3
EA201070247A1 (ru) Ингибиторы протеасом
EA200801362A1 (ru) Пиримидинил бензотиофеновые соединения
EA201201533A1 (ru) Prlr-специфическое антитело и его применения
MX2007011545A (es) Combinaciones para el tratamiento de cancer que comprenden el anticuerpo anti-egfr e inhibidores de vegfr.
TW200714604A (en) Substituted heterocycles and the uses thereof
EA201070636A1 (ru) Ингибирование рецептора белка, стимулирующего макрофаги (ron), и способы его лечения
EA200701930A1 (ru) Производные пиримидина для лечения гиперпролиферативных нарушений
UA99602C2 (ru) Антитело, специфически связывающееся с jam-a, способное ингибировать пролиферацию опухолевых клеток
MX2021003187A (es) Inhibición de la peptidasa específica de ubiquitina 9x.
TW200621260A (en) Selected fused heterocyclics and uses thereof
EA200702634A1 (ru) Гуманизированные антитела, специфичные в отношении nogo-a, и их фармацевтические применения